Covetrus and MWI Animal Health have reached a definitive agreement to merge, forming a combined company that will deliver a comprehensive range of products and solutions to veterinary practices. Under the transaction\u2019s terms, MWI\u2019s parent company, Cencora, will receive $1.25 billion in upfront cash, $800 million in preferred equity, and $1.45 billion in common equity in the merged business. The deal values MWI at $3.5 billion in enterprise value and gives Cencora a non-controlling 34.3% common equity stake in the combined company.<\/p>\n
The merger will unite MWI\u2019s extensive distribution capabilities with Covetrus\u2019 technology-enabled services, creating an integrated animal health platform that supports companion, equine, and production animal markets. Leaders from both companies claim that the deal will enhance access to products and services for veterinarians, producers, manufacturers, distributors, and pet owners.<\/p>\n
\u201cOur mission has always been to empower veterinary practices to work smarter and deliver better care,\u201d said Ben Wolin, president and CEO of Covetrus. \u201cBy bringing MWI\u2019s strong distribution capabilities and expertise to our business, we can offer more solutions to more customers, improve logistics, create savings, and develop innovative new ways to support the animal health ecosystem.\u201d<\/p>\n
According to the companies, the merged business will focus on improving efficient operations and expanding access to animal health products and services. By combining MWI\u2019s supply chain expertise with Covetrus\u2019 pharmacy and practice management solutions, the deal could yield cost savings for veterinary practices.<\/p>\n
Cencora\u2019s leadership also highlighted the transaction’s strategic nature. \u201cThis transaction positions MWI for success with a partner strategically focused on and dedicated to animal health, while allowing Cencora to further invest in our key growth priorities,\u201d said Bob Mauch, Cencora\u2019s president and CEO.<\/p>\n
Completion of the merger remains subject to customary closing conditions, including regulatory approvals. Cencora has noted that it does not expect the transaction to close before the end of its fiscal year on September 30, 2026.<\/p>\n
Once finalized, the combined animal health platform is expected to offer a broader set of resources and tools to support the veterinary profession, enhance innovation adoption, and address evolving needs across the animal health industry.<\/p>\n","protected":false},"excerpt":{"rendered":"
The union will create an expanded platform supporting the companion, equine, and production animal markets.<\/p>\n","protected":false},"author":823,"featured_media":79120,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"iawp_total_views":0,"footnotes":""},"categories":[90],"tags":[],"class_list":["post-79119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-online","column-news","clinical_topics-news"],"acf":{"hide_sidebar":false,"hide_sidebar_ad":false,"hide_all_ads":false},"yoast_head":"\n